TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18048574
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of atorvastatin and amlodipine
Study: 16221232
Drug: HB‐AS04 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB‐AS04 vaccine (Fendrix, GlaxoSmithKline Biologicals)
Study: 16221232
Drug: Standard vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard vaccine (Engerix, GlaxoSmithKline Biologicals)
Study: 7757309
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nimodipine t.i.d. for 7 days
Study: 31987248
Drug: Korean red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean red ginseng (KRG) 3 g for 6 weeks
Study: 29556335
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with β‐aminoisobutyric acid in Dahl salt-sensitive rats
Study: 25731657
Drug: Carbetocin (100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (100 μg IM)
Study: 23418994
Drug: TABADO program
Approvals — FDA: no, EMA: no, PMDA: no
Description: TABADO program (community-based smoking cessation program) including general information session, small-group sessions, individual counselling, and nicotine therapy if needed.
Study: 16476840
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa at a dose of 10,000 U thrice weekly s.c.
Study: 10607690
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) during induction and maintenance therapy
Study: 10607690
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without further ATRA
Study: 10607690
Drug: No ATRA
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No ATRA and no chemotherapy
Study: 10607690
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with ATRA
Study: 9624473
Drug: Trimethoprim (TMP)
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim (TMP) 10 mg/kg/day and Sulfamethoxazole (SMX) 50 mg/kg/day
Study: 9624473
Drug: Pyrimethamine (P)
Normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrimethamine (P) 50 mg/day and Sulfadiazine (S) 60 mg/kg/day
Study: 2966017
Drug: t‐PA 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: t‐PA 25 mg and UK 0.5 million U (group I)
Study: 2966017
Drug: t‐PA 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: t‐PA 25 mg and UK 1.0 million U (group II)
Study: 2966017
Drug: t‐PA 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: t‐PA 1.0 mg/kg and UK 0.5 million U (group III)
Study: 2966017
Drug: t‐PA 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: t‐PA 1.0 mg/kg and UK 1.0 million U (group IV)
Study: 2966017
Drug: t‐PA 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: t‐PA 1.0 mg/kg and UK 2.0 million U (group V)
Study: 27741182
Drug: 24-hour interval
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour interval administration of mifepristone and misoprostol
Study: 27741182
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of mifepristone and misoprostol
Study: 25133876
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (ICS) for 8 weeks
Study: 8573621
Drug: AdCFTR (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AdCFTR (2 x 10^5 to 2 x 10^8.5 plaque forming units) administered to the nasal epithelium of one nostril
Study: 2596317
Drug: Acetazolamide 20
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide 20 mg/kg/day
Study: 31504868
Drug: Increasing maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing maintenance methadone dose by 30%
Study: 31504868
Drug: Adding oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adding oxycodone
Study: 31504868
Drug: Adding a
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adding a single dose of gabapentin
Study: 31504868
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (usual OAT dose)
Study: 21756523
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV methylprednisolone (MP) followed by oral MP (125 mg bolus, followed by 40 mg 6 hourly and then oral MP 0.6 mg/kg/day for 2 weeks)
Study: 21756523
Drug: IV hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV hydrocortisone (HC) followed by oral prednisolone (200 mg 6 hourly until discharge, followed by prednisolone 0.75 mg/kg/day for 2 weeks)
Study: 19888784
Drug: ALO-01 whole
Normalized name: ALOE ARBORESCENS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALO-01 whole (60 mg capsules)
Study: 19888784
Drug: ALO-01 crushed
Normalized name: aloe polysaccharide 0.01 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALO-01 crushed (60 mg capsules)
Study: 19888784
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate solution (MSS) (120 mg)
Study: 7595265
Drug: Pharmacotherapy consultation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacotherapy consultation
Study: 31416827
Drug: Dexamethasone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.6 mg/kg)
Study: 773507
Drug: Oxygen administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administered by MC mask throughout the first 24 hours in hospital
Study: 773507
Drug: Air administered
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air administered by MC mask throughout the first 24 hours in hospital
Study: 14757900
Drug: Interdisciplinary rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary rehabilitation program (7 weeks duration, including pain school, cognitive behavioral therapy, gradual withdrawal of pain-relieving drugs)
Study: 971966
Drug: Home care
Normalized name: Alpha Dent Home Care 0.4% Fluoride Treatment Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home care as part of treatment
Study: 971966
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hospital treatment)
Study: 25138765
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (500 mg on day 1 and then 250 mg/day for 5 days)
Study: 25138765
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline (200 mg/day for 1 month)
Study: 23161899
Drug: GLPG0259 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG0259 (50 mg once daily)
Study: 22686551
Drug: Telephone-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based cognitive-behavioral therapy (CBT)
Study: 10684841
Drug: Topical nipradilol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nipradilol (0.25%)
Study: 9344406
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (ERT) with tacrine (80 mg/day, 120 mg/day, or 160 mg/day)
Study: 9344406
Drug: Tacrine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrine (80 mg/day, 120 mg/day, or 160 mg/day) without ERT
Study: 2943811
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (plasma-derived and recombinant)
Study: 31971071
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of VRT and CPT (COMB)
Study: 29846887
Drug: BI 425809
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 425809 10, 25, 50 or 75 mg once daily or 75 mg twice daily (young subjects); 25 mg or 50 mg once daily (elderly subjects)
Study: 26713415
Drug: Brace treatment
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace treatment for patellofemoral OA
Study: 6742895
Drug: Intraarticular steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular steroids
Study: 25176136
Drug: Ivabradine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (up to 10 mg twice daily)
Study: 12475163
Drug: Mixed treatment
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed treatment (control appliance followed by stabilization appliance)
Study: 479385
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg nefopam hydrochloride
Study: 479385
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg nefopam hydrochloride
Study: 30929028
Drug: Intervention patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention patients with high pre‐treatment anxiety
Study: 28127827
Drug: Pragmatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pragmatic treatment of the lumbar spine and prescriptive treatment of bilateral hips (LBP + HIP)
Study: 28127827
Drug: Pragmatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pragmatic treatment of the lumbar spine only (LBP)
Study: 25830267
Drug: Arthroscopic shoulder
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic shoulder capsular release and manipulation, followed by a stretching program (twice daily for at least 15 minutes for 3 months)
Study: 25830267
Drug: Home therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home therapy program consisting of terminal range of motion low-grade stretches (twice daily for at least 15 minutes for 3 months)
Study: 21339317
Drug: Optimal pharmacological
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal pharmacological treatment (OPT)
Study: 10356602
Drug: Anticoagulants (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants (specific type not mentioned)
Study: 1826454
Drug: Recombinant interferon‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon‐alpha 2a (rIFN alpha 2a) administered alone (273 men)
Study: 1826454
Drug: Recombinant interferon‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon‐alpha 2a (rIFN alpha 2a) with escalating doses (3, 9, and 18 million I.U. daily for 3 days, then 36 million I.U. daily)
Study: 1826454
Drug: Recombinant interferon‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon‐alpha 2a (rIFN alpha 2a) at a dose of 36 million I.U. daily for approximately 10 weeks followed by maintenance schedule
Study: 25123061
Drug: DHA-rich intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich intervention supplement capsules consumed over the course of pregnancy
Study: 19243711
Drug: Cyclobenzaprine extended-release
Normalized name: cyclobenzaprine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine extended-release 15 mg
Study: 19243711
Drug: Cyclobenzaprine extended-release
Normalized name: cyclobenzaprine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine extended-release 30 mg
Study: 15764049
Drug: Adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene gel 0.1% plus clindamycin topical solution 1%
Study: 15764049
Drug: Clindamycin topical
Normalized name: clindamycin topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin topical solution 1% alone
Study: 15764049
Drug: Adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene gel 0.1% alone
Study: 9639376
Drug: NEP inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEP inhibitor candoxatrilat (125 nmol/min)
Study: 9639376
Drug: NEP inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEP inhibitor thiorphan (30 nmol/min) after placebo
Study: 9639376
Drug: NEP inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEP inhibitor thiorphan (30 nmol/min) after enalapril (20 mg)
Study: 9639376
Drug: NEP inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEP inhibitor thiorphan (30 nmol/min)
Study: 9639376
Drug: Endothelin ETA
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin ETA antagonist BQ‐123 (100 nmol/min)
Study: 9639376
Drug: NEP inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEP inhibitor thiorphan (30 nmol/min) in hypertensive patients
Study: 8404404
Drug: Olsalazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine (2 g daily)
Study: 8079106
Drug: Mesalazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine (2 g or 6 g daily)
Study: 8079106
Drug: Control (pre-medication)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (pre-medication)
Study: 1269844
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily injections
Study: 30969032
Drug: Combined 8.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 8.3 mg Nestorone® and 62.5 mg Testosterone gel (Nes-T)
Study: 30969032
Drug: 62.7 mg
Normalized name: AVOBENZONE 25.1 mg in 1 mL / HOMOSALATE 62.7 mg in 1 mL / OCTISALATE 41.8 mg in 1 mL / OCTOCRYLENE 22.9 mg in 1 mL / OXYBENZONE 16.7 mg in 1 mL TOPICAL LOTION [Australian Gold BOAD SPECTRUM SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 62.7 mg Testosterone gel
Study: 31323067
Drug: Macintosh laryngoscope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macintosh laryngoscope (ML)
Study: 22333218
Drug: Bosentan treatment
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan treatment
Study: 12511540
Drug: BNP infusion
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP infusion (60, 120, and 180 pmol/min)
Study: 12511540
Drug: BNP infusion
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP infusion (180 pmol/min)
Study: 8965117
Drug: Copolymer 1
Normalized name: glatiramer (copolymer 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copolymer 1 (Copaxone) 20 mg daily subcutaneous injection for at least 1 year
Study: 1814318
Drug: Oral magnesium-lactate-citrate
Normalized name: calcium lactate / magnesium citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral magnesium-lactate-citrate for 6 weeks
Study: 1814318
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (30 mmol daily for 7 days)
Study: 30496533
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Treatment for Insomnia (CBT-I)
Study: 30496533
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Treatment for Pain (CBT-P)
Study: 24380637
Drug: Run-off CTA
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Run-off CTA with 40 mL of contrast medium (injection rate of 6 mL/s)
Study: 19527338
Drug: TA-loaded lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA-loaded lipid nanocarriers (TA-LNCs) incorporated into a hydrophilic gel and foam
Study: 19527338
Drug: Saturated TA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saturated TA solution in silicon oil
Study: 17475733
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (augmentation with citalopram)
Study: 17475733
Drug: Medication augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication augmentation (sustained-release bupropion or buspirone)
Study: 17475733
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to cognitive therapy
Study: 17475733
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to another antidepressant (sertraline, sustained-release bupropion, or extended-release venlafaxine)
Study: 15064269
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at 75 ng*mL(‐1)
Study: 15064269
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at 0 ng*mL(‐1) (Group 0)
Study: 15064269
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at 25 ng*mL(‐1) (Group 25)
Study: 15064269
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at 50 ng*mL(‐1) (Group 50)
Study: 15064269
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at 75 ng*mL(‐1) (Group 75)
Study: 8507125
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of K8515 ingested in a prehydrated form three times a day with meals
Study: 8507125
Drug: 6.7 g
Normalized name: ALCOHOL 16.7 g in 30 mL TOPICAL SPRAY [HS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.7 g of K8515 three times a day
Study: 24231560
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (prednisolone 4 mg/kg/day over 1 week and 2mg/kg/day for the next 3 weeks)
Study: 24231560
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (prednisolone 4 mg/kg/day over 4 weeks)
Study: 22402793
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine patch (Lidoderm(®), Endo Pharmaceuticals)
Study: 20097702
Drug: Dalcetrapib 900
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib 900 mg/day with atorvastatin
Study: 19069460
Drug: Bismuth tri‐potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth tri‐potassium di‐citrate (De-Nol) 120 mg thrice daily with meteospasmyl (spasmolytic and antifoaming agent) for 3 weeks
Study: 19069460
Drug: Aluminium phosphate
Normalized name: Aluminium phosphate
DrugBank: Aluminium phosphate (DB14517)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aluminium phosphate with meteospasmyl (1 capsule thrice daily) for 3 weeks
Study: 16162940
Drug: Simvastatin, 80
Normalized name: Simvastatin, 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 80 mg/day
Study: 14702121
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg/day for 10 days
Study: 14702121
Drug: Clarithromycin 1000
Normalized name: clarithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 1000 mg/day for 10 days
Study: 10394976
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg CPFX plus 600 mg CAM (combination group)
Study: 10394976
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg CPFX (CPFX group)
Study: 10394976
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg CPFX plus 600 mg CAM (combination group) in patients with an indwelling catheter
Study: 10394976
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg CPFX (CPFX group) in patients with an indwelling catheter
Study: 8785404
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (800 to 3200 mg/day) for 12 weeks
Study: 1804644
Drug: Ro 23‐6152
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 23‐6152 30 mg
Study: 1804644
Drug: Ro 23‐6152
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 23‐6152 80 mg
Study: 1804644
Drug: Ro 23‐6152
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 23‐6152 10 mg
Study: 27721230
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (1800 mg daily for 4 months)
Study: 25509696
Drug: Calcium gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium gluconate intravenous use
Study: 19717476
Drug: Salmeterol/Fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/Fluticasone propionate combination (SFC)
Study: 18847425
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with an ACE inhibitor (perindopril) and a diuretic (indapamide) in fixed doses
Study: 18847425
Drug: Direct renin
Normalized name: DIRECT RENIN INHIBITOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct renin inhibitors
Study: 17145988
Drug: Overnight hospitalization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight hospitalization and abciximab bolus and infusion (group 2)
Study: 11461738
Drug: Digoxin and
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin and diuretics
Study: 2170885
Drug: Estrogen/progestin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen/progestin therapy
Study: 11174874
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no hormone replacement therapy)
Study: 9179430
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal spray (200 micrograms once daily for 14 days)